|
1 Simsir A, Ioffe OB, Bourquin P, et al. Repeat cervical cytology at the time of colposcopy. Is there an added benefit? Acta Cytol, 2001, 45(1)：23–27.
|
|
2 Wright TC Jr, Cox JT, Massad LS, et al. 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. AJOG, 2003，189(1)：295–304.
|
|
3 Gornall RJ, Boyd IE, Manolitsas T, et al. Interval cervical cancer following treatment for cervical intraepithelial neoplasia. Int J Gynecol Cancer, 2000, 10(3)：198–202.
|
|
4 Spitzer M, Apgar BS, Brotzman GL. Management of histologic abnormalities of the cervix. Am Fam Physician, 2006, 73(1): 105–112.
|
|
5 Wang N, Emancipator SN, Rose P, et al. Histologic follow–up of atypical endocervical cells. Liquid–based, thin–layer preparation vs. conventional papsmear. Acta Cytologica, 2002, 46(3)：453–456.
|
|
6 Gupta D, Kannan V, Komaromy–Hiller G, et al. ASCUS, mature metaplastic type. Cytologic diagnosis and follow–up. Acta Cytocolgica, 2001, 45(2)：192–196.
|
|
7 Alves VA, Bibbo M, Schmitt FC, et al. Comparison of manual and automated methods of liquid–based cytology. A morphologic study. Acta Cytol, 2004, 48(2): 187–193.
|
|
8 Lonky NM, Navarre GL, Saunders S, et al. Low–grade papanicolaou smears and the bethesda system：A prospective cytohistopathologic analysis. Obstet Gynecol, 1995, 85(5 pt 1)：716–721.
|
|
9 Bernstein SJ, Sanchez–Ramos L, Ndubisi B. Liquid–based cervical cytologic smear study and conventional Papanicolaou smears: A meta–analysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol, 2001，185(2)：308–317.
|
|
10 Pan Q, Belinson JL, Li L, et al. A thin–layer, liquid–based pap test for mass screening in an area of China with a high incidence of cervical carcinoma. A cross–sectional, comparative study. Acta Cytol, 2003, 47(1)：45–50.
|
|
11 Bosch FX, Manos MM, Munöz N, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst, 1995, 87(11)：796–802.
|
|
12 Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 2003, 348(6)：518–527.
|
|
13 Azodi M, Chambers SK, Rutherford TJ, et al. Adenocarcinoma in situ of the cervix: Management and outcome. Gynecol Oncol, 1999, 73(3): 348–353.
|
|
14 Hernández–Hernández DM, Ornelas–Bernal L, Guido–Jiménez M, et al. Association between high–risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexican women. Gynecol Oncol, 2003, 90(2): 310–317.
|
|
15 Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol, 2005, 6(4)：204.
|
|
16 Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10–year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type–specific HPV testing in clinical practice. J Natl Cancer Inst, 2005, 97(14)：1072–1079.
|
|
17 Cen JM, Qian DY, Wang D, et al. Evaluation of high–risk HPV testing in triage of patients with atypical squamous cells of undetermined significance. Chin J Obs/Gynecol & Pediatr(Electronic Version), 2006, 2(1)：12–14.[岑坚敏，钱德英，王丁，等. 高危型人类乳头瘤病毒检测对不典型鳞状细胞分流监测的临床价值. 中华妇幼临床医学杂志：电子版，2006，2(1)：12–14.]
|
|
18 Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical–cancer screening：A prospective study. Lancet, 1999, 354(9172)：20–25.
|
|
19 Sun CA, Liu JF, Wu DM, et al. Viral load of high–risk human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynaecol Obstet, 2002, 76(1)：41–47.
|
|
20 Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high–grade cervical lesions：A study of 7 932 women. Br J Cancer, 2001, 84(12)：1616–1623.
|
|
21 Kuhn L, Denny L, Pollack A, et al. Human papillomavirus DNA testing for cervical cancer screening in low–resource settings. J Natl Cancer Inst, 2000, 92(10)：818–825.
|
|
22 Strickler HD, Palefsky JM, Shah KV, et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus–seropositive women. J Natl Cancer Inst, 2003, 95(14)：1062–1071.
|
|
23 Screening and cloning of the down–regulation gene by recombinant interferon–B using suppression subtractive hybridization technique. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 2006, 20(3): 273–275.
|
|
24 Wright TC Jr, Cox JT, Massad LS, et al. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA, 2002, 287(16)：2120–2129.
|
|
25 Belinson JL, Qiao YL, Pretorius RG, et al. Shanxi Province cervical cancer screening study Ⅱ：Self–sampling for high–risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. Int J Gynecol Cancer, 2003, 13(6)：819–826.
|
|
26 Qiao YL, Zhang WH, Li L, et al. The cross sectional study in screening cervical carcinoma. Acta Academiae Med Sinicae, 2002, 24(1)：50–53.[乔友林，章文华，李凌，等. 子宫颈癌筛查方法的横断面比较研究. 中国医学科学院学报，2002, 24(1)：50–53.]
|
|
27 Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med, 2003, 127(8)：959–968.
|
|
28 Lorenzato F, Singer A, Mould T, et al. Cervical cancer detection by hybrid capture and evaluation of local risk factors. Int J Gynaecol Obstet, 2001, 73(1)：41–46.
|
|
29 Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin, 2002, 52(6)：342–362.
|
|
30 Ho L, Terry G, Londesborough P, et al. Human papillomavirus DNA detection in the management of women with twice mildly abnormal cytological smears. J Med Virol, 2003, 69(1)：118–121.
|